MKM Partners Reiterates Buy on Oclaro (OCLR) - PT to $11

Pre-Open Stock Movers 11/02: (PTN) (AVXS) (EGRX) Higher; (ADPT) (CEMP) (DXCM) Lower (more...)

Today's Pre-Open Stock Movers

Adeptus Health (NYSE: ADPT) 57.9% LOWER; reported Q3 EPS of $0.06, $0.50 worse than the analyst estimate of $0.56. Revenue for the quarter came in at $85.4 million versus the consensus estimate of $89.99 million.

Palatin Technologies, Inc. (NYSE: PTN) 36.3% HIGHER; announced positive, statistically significant top-line results from the Reconnect Studies, its Phase 3 clinical trial program of lead drug candidate bremelanotide. The Reconnect Studies, investigating bremelanotide as an on-demand treatment for premenopausal women diagnosed with hypoactive sexual desire disorder ("HSDD"), met... More

Needham & Company Raises price Target on Oclaro (OCLR) to $14

Needham & Company reiterated a Strong Buy rating on Oclaro (NASDAQ: OCLR), and raised the price target to $14.00 (from $11.00), following the company's 1Q report. Oclaro visited ZTE last week. ZTE expects very strong optical growth on a continuing basis in CY4Q and CY17.

Analyst Alex... More

After-Hours Stock Movers 11/01: (PTN) (AVXS) (EA) Higher; (ADPT) (ZAGG) (DXCM) Lower (more...)

Today's After-Hours Movers

Adeptus Health (NYSE: ADPT) 48% LOWER; reported Q3 EPS of $0.06, $0.50 worse than the analyst estimate of $0.56. Revenue for the quarter came in at $85.4 million versus the consensus estimate of $89.99 million.

Palatin Technologies, Inc. (NYSE: PTN) 46.9% HIGHER; announced positive, statistically significant top-line results from the Reconnect Studies, its Phase 3 clinical trial program of lead drug candidate bremelanotide. The Reconnect Studies, investigating bremelanotide as an on-demand treatment for premenopausal women diagnosed with hypoactive sexual desire disorder ("HSDD"), met the... More

Oclaro (OCLR) Tops Q1 EPS by 4c

Oclaro (NASDAQ: OCLR) reported Q1 EPS of $0.14, $0.04 better than the analyst estimate of $0.10. Revenue for the quarter came in at $135.5 million versus the consensus estimate of $131.65 million.

For earnings history and earnings-related data on Oclaro (OCLR) click here.

Trading Radar for 11/1: Kellogg (K), Electronic Arts (EA), Mosaic (MOS), Herbalife (HLF), Western Union (WU) Report

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Earnings:

Adeptus Health (NYSE: ADPT) - consensus EPS $0.56
Aircastle Limited (NYSE: AYR) - consensus EPS $0.43
Allot Communications (Nasdaq: ALLT) - consensus EPS $0.02
Ameresco (NYSE: AMRC) - consensus EPS $0.09
Ametek (NYSE: AME) - consensus EPS $0.55
Ampco-Pittsburgh (NYSE: AP) - no Street consensus... More

Options with volatility and volume movement:

Options with increasing implied volatility: OCLR SCO ABC ULTA SPXU SPXS LLY MCK QID PFE

Options with decreasing implied volatility: INFN AKAM GRUB CRUS NXPI BWLD P VMW S SWFT EXPE JNPR

Oclaro (OCLR): Buy Ahead Of The Quarter - Needham

Needham & Company analyst, Alex Henderson, stepped up to the plate and reiterated his Strong Buy rating on shares of Oclaro (NASDAQ: OCLR) and raised the price target to $11 from $10 indicating confidence in a beat and raise quarter despite the recent volatility in optical... More